Madrigal Pharmaceuticals Aktie
435,80
EUR
-6,40
EUR
-1,45
%
506,22
USD
+7,49
USD
+1,50
%
Madrigal Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Madrigal Pharmaceuticals Aktie Analyse
| 10.06.19 | Madrigal Pharmaceuticals Buy | B. Riley FBR | |
| 28.02.19 | Madrigal Pharmaceuticals Buy | H.C. Wainwright & Co. | |
| 14.12.18 | Madrigal Pharmaceuticals Outperform | Wolfe Research | |
| 12.12.18 | Madrigal Pharmaceuticals Neutral | B. Riley FBR | |
| 01.06.18 | Madrigal Pharmaceuticals Outperform | Oppenheimer & Co. Inc. | |
| 01.06.18 | Madrigal Pharmaceuticals Buy | H.C. Wainwright & Co. | |
| 30.01.18 | Madrigal Pharmaceuticals Buy | H.C. Wainwright & Co. | |
| 06.12.17 | Madrigal Pharmaceuticals Buy | H.C. Wainwright & Co. | |
|
Werbung
|
|||
| 29.11.17 | Madrigal Pharmaceuticals Buy | H.C. Wainwright & Co. | |
Werbung
Werbung